Catalog No.
DHC22401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
CCP, PDN-21, CALCA, Calcitonin carboxyl-terminal peptide, Calcitonin, CALC1, Calcitonin gene-related peptide II, CALCB, Calcitonin gene-related peptide 2, Beta-CGRP, CALC2, CGRP-II, Beta-type CGRP
Concentration
0.63 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01258 & P10092
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LY-2951742, galcanezumab-gnlm, CAS: 1578199-75-3
Clone ID
Galcanezumab
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study, PMID: 30446596
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials, PMID: 32426040
Galcanezumab for migraine, PMID: 32921891
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial, PMID: 29813147
Galcanezumab: First Global Approval, PMID: 30378008
Trial of Galcanezumab in Prevention of Episodic Cluster Headache, PMID: 31291515
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial, PMID: 29848108
Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review, PMID: 32319039
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial, PMID: 32949542
Galcanezumab for the prevention of cluster headache, PMID: 32702245
Galcanezumab, PMID: 31643470
An Evidence-Based Review of Galcanezumab for the Treatment of Migraine, PMID: 33010021
Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies, PMID: 30594122
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache, PMID: 32504377
Galcanezumab, PMID: 30372007
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine, PMID: 30413151
Galcanezumab for the prevention of migraine, PMID: 33291980
Reducing Episodic Cluster Headaches: Focus on Galcanezumab, PMID: 32753938
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination, PMID: 31159727
The treatment efficacy of galcanezumab for migraine: A meta-analysis of randomized controlled trials, PMID: 31581028
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial, PMID: 29255900
Galcanezumab CONQUERs migraine prevention, PMID: 32949530
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis, PMID: 32006159
Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention, PMID: 30681655
Migraine overview and summary of current and emerging treatment options, PMID: 30681821
Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy, PMID: 31043785
Galcanezumab for the Management of Migraine: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials, PMID: 33376635
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine, PMID: 33143451
Drug profile: galcanezumab for prevention of cluster headache, PMID: 33206562
Galcanezumab (Emgality) for Migraine and Cluster Headaches, PMID: 32293845
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database, PMID: 33435709
Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache, PMID: 32055802
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study, PMID: 29310444
Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine, PMID: 32340471
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure, PMID: 31104507
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies, PMID: 31952501
A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody, PMID: 30917684
Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine, PMID: 32845740
Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine, PMID: 31482569
Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability, PMID: 31270220
Monoclonal antibodies for the prevention of migraine, PMID: 31550937
Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials, PMID: 30942898
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2), PMID: 31253091
Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials), PMID: 33069214
CGRP as the target of new migraine therapies - successful translation from bench to clinic, PMID: 29691490
Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies, PMID: 31595600
CGRP Antibodies as Prophylaxis in Migraine, PMID: 30550780
Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine, PMID: 32429851
Role of CGRP in Migraine, PMID: 30725283
What's New in the Treatment of Migraine?, PMID: 31393282
For research use only. Not for human or drug use.
